首页> 美国卫生研究院文献>Aging (Albany NY) >ANXA7 promotes the cell cycle proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L
【2h】

ANXA7 promotes the cell cycle proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L

机译:ANXA7通过上调CDC5L促进多发性骨髓瘤细胞的细胞周期增殖和细胞粘附介导的耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study aimed to investigate whether annexin A7 (ANXA7) could promote the cell cycle, proliferation and cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma (MM) cells by up-regulating cell division cycle 5-like (CDC5L). As a result, ANXA7 expression was increased in the serum of MM patients and the expression of ANXA7 and CDC5L was also increased in MM cell lines. ANXA7 overexpression promoted the proliferation and cycle of U266 and RPMI8226 cells. The expression of proliferation cell nuclear antigen (PCNA), KI67, cyclin dependent kinase 1 (CDK1) and cyclinB1 in transfected cells was consistent with the changes of proliferation and cell cycle. In co-culture system of BMSC cells and MM cells, expression of CD44, ICAM1 and VCAM1 in MM cells was increased, which was further increased by ANXA7 overexpression. Bortezomib could increase the apoptosis of U266 and RPMI8226 cells. In co-culture system of BMSC cells and MM cells, the promotion effects of bortezomib on apoptosis of MM cells was decreased, which was further suppressed by ANXA7 overexpression. The above effects exerted by ANXA7 overexpression could be reversed by ANXA7 interference. Moreover, ANXA7 was proved to be combined with CDC5L. CDC5L interference could inhibit the promotion effects of ANXA7 overexpression on proliferation and cell cycle and inhibition effects of ANXA7 overexpression on apoptosis of MM cells treated with bortezomib in co-culture system. In conclusion, ANXA7 could promote the cell cycle, proliferation and CAM-DR of MM cells by up-regulating CDC5L.
机译:这项研究旨在研究膜联蛋白A7(ANXA7)是否可以通过上调细胞分裂周期5类(CDC5L)来促进多发性骨髓瘤(MM)细胞的细胞周期,增殖和细胞粘附介导的耐药性(CAM-DR) 。结果,MM患者血清中ANXA7表达增加,并且MM细胞系中ANXA7和CDC5L的表达也增加。 ANXA7过表达促进了U266和RPMI8226细胞的增殖和周期。转染细胞中增殖细胞核抗原(PCNA),KI67,细胞周期蛋白依赖性激酶1(CDK1)和cyclinB1的表达与细胞增殖和周期的变化一致。在BMSC细胞和MM细胞的共培养系统中,MM细胞中CD44,ICAM1和VCAM1的表达增加,而ANXA7过表达进一步增加了CD44,ICAM1和VCAM1的表达。硼替佐米可以增加U266和RPMI8226细胞的凋亡。在BMSC细胞和MM细胞的共培养系统中,硼替佐米对MM细胞凋亡的促进作用降低,而ANXA7过表达进一步抑制了硼替佐米的生长。 ANXA7过表达所产生的上述效应可能会被ANXA7干扰逆转。此外,ANXA7被证明与CDC5L结合使用。 CDC5L干扰可以抑制ANXA7过表达对增殖和细胞周期的促进作用,以及ANXA7过表达对硼替佐米处理的MM细胞共培养系统的抑制作用。总之,ANXA7可以通过上调CDC5L来促进MM细胞的细胞周期,增殖和CAM-DR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号